Patents Assigned to ChromaDex, Inc.
  • Patent number: 10280190
    Abstract: Derivatives of nicotinic acid riboside (NAR), nicotinamide riboside (NR), and reduced NAR and NR, including 1-(2?,3?,5?-triacetyl-beta-D-ribofuranosyl)-1,4-dihydronicotinic acid (4a), and compositions containing the same and/or reduced derivative forms of nicotinamide riboside including 1-(2?,3?,5?-triacetyl-beta-D-ribofuranosyl)-1,4-nicotinamide (2), are provided for use in the care of treatment of skin and skin conditions. In some embodiments, the invention relates to pharmaceutical compositions and cosmetic compositions containing one or more NR, NAR, NRH, or NARH derivatives, or prodrugs or salts thereof. In further embodiments, the invention relates to methods of using one or more NR, NAR, NRH, or NARH derivatives, or prodrugs, solvates, or salts thereof, to promote the increase of intracellular levels of nicotinamide adenine dinucleotide (NAD+) in cells and tissues for improving cell and tissue survival and overall cell and tissue health.
    Type: Grant
    Filed: March 16, 2016
    Date of Patent: May 7, 2019
    Assignees: ChromaDex, Inc., The Queen's University of Belfast
    Inventors: Ryan Dellinger, Marie Eugenie Migaud, Philip Redpath, Troy Rhonemus, Richard Cunningham
  • Patent number: 10183036
    Abstract: Compositions are provided including nicotinic acid riboside (“NAR”), and derivatives thereof including 1-(2?,3?,5?-triacetyl-beta-D-ribofuranosyl)-nicotinic acid (“NAR triacetate” or “NARTA”); or derivatives of a reduced form of nicotinic acid riboside (“NARH”), including 1-(2?,3?,5?-triacetyl-beta-D-ribofuranosyl)-1,4-dihydronicotinic acid (“NARH triacetate” or “NARH-TA”); or derivatives of nicotinamide riboside (“NR”), including 1-(2?,3?,5?-triacetyl-beta-D-ribofuranosyl)-nicotinamide (“NR triacetate” or “NRTA”); derivatives of a reduced form of nicotinamide riboside (“NRH”), including 1-(2?,3?,5?-triacetyl-beta-D-ribofuranosyl)-1,4-dihydronicotinamide (“NRH triacetate” or “NRH-TA”); or salts or prodrugs thereof, for use in food or beverage applications, pharmaceutical formulations, or as a dietary supplement.
    Type: Grant
    Filed: April 20, 2017
    Date of Patent: January 22, 2019
    Assignee: ChromaDex Inc.
    Inventors: Ryan Dellinger, Troy Rhonemus, Mark Morris, Aron Erickson, Hadi Casser, Marie Eugenie Migaud
  • Publication number: 20180258127
    Abstract: The present disclosure provides nicotinate/nicotinamide riboside compounds or derivatives of formula (I): wherein X?, Z1, Z2, n, R1, R2, R3, R4, R5, R6, R7, and R8 are described herein, reduced analogs thereof, and synthetic processes for the preparation thereof.
    Type: Application
    Filed: May 11, 2018
    Publication date: September 13, 2018
    Applicants: ChromaDex Inc., The Queen's University of Belfast
    Inventors: Marie Eugenie Migaud, Philip Redpath, Kerri Crossey, Richard Cunningham, Ryan Dellinger, Troy Rhonemus, Sylesh Venkataraman, Brian Nettles
  • Patent number: 10039725
    Abstract: A method is provided for treating an individual for a cellular proliferative disorder, including administering to the individual in need of such treatment a therapeutically effective amount of the compound pterostilbene wherein UDP-glucuronosyltransferase (UGT) activity is increased. In an embodiment, 12-HETE levels can be reduced by administration of pterostilbene.
    Type: Grant
    Filed: September 22, 2014
    Date of Patent: August 7, 2018
    Assignees: ChromaDex Inc., The Regents of the Unviersity of California
    Inventors: Jeremy Bartos, Ryan Dellinger
  • Patent number: 10000520
    Abstract: The present disclosure provides nicotinate/nicotinamide riboside compounds or derivatives of formula (I): wherein X?, Z1, Z2, n, R1, R2, R3, R4, R5, R6, R7, and R8 are described herein, reduced analogs thereof, and synthetic processes for the preparation thereof.
    Type: Grant
    Filed: March 16, 2017
    Date of Patent: June 19, 2018
    Assignees: ChromaDex Inc., The Queen's University of Belfast
    Inventors: Marie Eugenie Migaud, Philip Redpath, Kerri Crossey, Richard Cunningham, Ryan Dellinger, Troy Rhonemus, Sylesh Venkataraman, Brian Nettles
  • Patent number: 9975915
    Abstract: The present disclosure provides novel crystalline forms of nicotinoyl riboside compounds or derivatives of formula (I): wherein X?, Z1, Z2, n, R1, R2, R3, R4, R5, R6, R7, and R8 are described herein, modified derivatives thereof, and phosphorylated analogs thereof, or salts, solvates, or prodrugs thereof; and methods of preparation thereof.
    Type: Grant
    Filed: November 10, 2017
    Date of Patent: May 22, 2018
    Assignees: The Queen's University of Belfast, ChromaDex Inc.
    Inventors: Marie Eugenie Migaud, Philip Redpath, Kerri Crossey, Richard Cunningham, Aron Erickson, Richard Nygaard, Amanda Storjohann
  • Publication number: 20180134742
    Abstract: The present disclosure provides novel crystalline forms of nicotinoyl riboside compounds or derivatives of formula (I): wherein X?, Z1, Z2, n, R1, R2, R3, R4, R5, R6, R7, and R8 are described herein, modified derivatives thereof, and phosphorylated analogs thereof, or salts, solvates, or prodrugs thereof, and methods of preparation thereof.
    Type: Application
    Filed: November 10, 2017
    Publication date: May 17, 2018
    Applicants: The Queen's University of Belfast, ChromaDex Inc.
    Inventors: Marie Eugenie Migaud, Philip Redpath, Kerri Crossey, Richard Cunningham, Aron Erickson, Richard Nygaard, Amanda Storjohann
  • Publication number: 20180134743
    Abstract: The present disclosure provides methods of making nicotinoyl riboside compounds or derivatives of formula (I): wherein X?, Z1, Z2, n, R1, R2, R3, R4, R5, R6, R7, and R8 are described herein, reduced analogs thereof, modified derivatives thereof, phosphorylated analogs thereof, and adenylyl dinucleotide conjugates thereof, or salts, solvates, or prodrugs thereof; and novel crystalline forms thereof.
    Type: Application
    Filed: November 10, 2017
    Publication date: May 17, 2018
    Applicants: The Queen's University of Belfast, ChromaDex Inc.
    Inventors: Marie Eugenie Migaud, Philip Redpath, Kerri Crossey, Richard Cunningham, Aron Erickson, Richard Nygaard, Amanda Storjohann
  • Publication number: 20170304338
    Abstract: Compositions are provided including nicotinic acid riboside (“NAR”), and derivatives thereof including 1-(2?,3?,5?-triacetyl-beta-D-ribofuranosyl)-nicotinic acid (“NAR triacetate” or “NARTA”); or derivatives of a reduced form of nicotinic acid riboside (“NARH”), including 1-(2?,3?,5?-triacetyl-beta-D-ribofuranosyl)-1,4-dihydronicotinic acid (“NARH triacetate” or “NARH-TA”); or derivatives of nicotinamide riboside (“NR”), including 1-(2?,3?,5?-triacetyl-beta-D-ribofuranosyl)-nicotinamide (“NR triacetate” or “NRTA”); derivatives of a reduced form of nicotinamide riboside (“NRH”), including 1-(2?,3?,5?-triacetyl-beta-D-ribofuranosyl)-1,4-dihydronicotinamide (“NRH triacetate” or “NRH-TA”); or salts or prodrugs thereof, for use in food or beverage applications, pharmaceutical formulations, or as a dietary supplement.
    Type: Application
    Filed: April 20, 2017
    Publication date: October 26, 2017
    Applicant: Chromadex Inc.
    Inventors: Ryan Dellinger, Troy Rhonemus, Mark Morris, Aron Erickson, Hadi Casser, Marie Eugenie Migaud
  • Publication number: 20170296564
    Abstract: Methods for delivering at least one compound selected from nicotinamide riboside (NR), nicotinic acid riboside (NAR), and nicotinamide mononucleotide (NMN), derivatives thereof, or salts thereof, in combination with at least one of thiamine (vitamin B1), riboflavin (vitamin B2), niacin (vitamin B3), and pyridoxine (vitamin B6), to an infant human subject in need of said compound or compounds are provided.
    Type: Application
    Filed: April 14, 2017
    Publication date: October 19, 2017
    Applicant: ChromaDex, Inc.
    Inventors: Ryan Dellinger, Troy Rhonemus, Mark Morris, Dietrich Conze, Amy Boileau
  • Publication number: 20170267709
    Abstract: The present disclosure provides nicotinate/nicotinamide riboside compounds or derivatives of formula (I): wherein X?, Z1, Z2, n, R1, R2, R3, R4, R5, R6, R7, and R8 are described herein, reduced analogs thereof, and synthetic processes for the preparation thereof.
    Type: Application
    Filed: March 16, 2017
    Publication date: September 21, 2017
    Applicants: ChromaDex Inc., The Queen's University of Belfast
    Inventors: Marie Eugenie Migaud, Philip Redpath, Kerri Crossey, Richard Cunningham, Ryan Dellinger, Troy Rhonemus, Sylesh Venkataraman, Brian Nettles
  • Publication number: 20160355539
    Abstract: A synthetic process is provided for the preparation of phosphorylated analogs of nicotinamide riboside (“NR”) having the formula (I), or salts thereof, and reduced or modified derivatives thereof, having the formula (II), wherein X?, Y1, Y2, Z1, Z2, n, R1, R2, R3, R4, R5, R6, and R7 are as defined herein. The present disclosure also relates to the preparation of phosphorylated analogs of nicotinic acid riboside (“NAR”) having the formula (I), or salts thereof, and reduced or modified derivatives thereof, having the formula (II). Generally solvent-free conditions are employed using appropriate mechano-chemical techniques as described.
    Type: Application
    Filed: June 3, 2016
    Publication date: December 8, 2016
    Applicants: ChromaDex, Inc., The Queen's University of Belfast
    Inventors: Marie Eugenie Migaud, Philip Redpath, Kerri Crossey, Richard Cunningham, Troy Rhonemus, Sylesh Venkataraman
  • Publication number: 20160272668
    Abstract: Derivatives of nicotinic acid riboside (NAR), nicotinamide riboside (NR), and reduced NAR and NR, including 1-(2?,3?,5?-triacetyl-beta-D-ribofuranosyl)-1,4-dihydronicotinic acid (4a), and compositions containing the same and/or reduced derivative forms of nicotinamide riboside including 1-(2?,3?,5?-triacetyl-beta-D-ribofuranosyl)-1,4-nicotinamide (2), are provided for use in the care of treatment of skin and skin conditions. In some embodiments, the invention relates to pharmaceutical compositions and cosmetic compositions containing one or more NR, NAR, NRH, or NARH derivatives, or prodrugs or salts thereof. In further embodiments, the invention relates to methods of using one or more NR, NAR, NRH, or NARH derivatives, or prodrugs, solvates, or salts thereof, to promote the increase of intracellular levels of nicotinamide adenine dinucleotide (NAD+) in cells and tissues for improving cell and tissue survival and overall cell and tissue health.
    Type: Application
    Filed: March 16, 2016
    Publication date: September 22, 2016
    Applicants: ChromaDex Inc., The Queen's University of Belfast
    Inventors: Ryan Dellinger, Marie Eugenie Migaud, Philip Redpath, Troy Rhonemus, Richard Cunningham
  • Publication number: 20160250241
    Abstract: Compositions containing nicotinamide riboside (NR) are provided. NR containing compositions are used in the care or treatment of skin and skin conditions. In some embodiments, the invention relates to pharmaceutical compositions and cosmetic compositions containing nicotinamide riboside. In further embodiments, the invention relates to methods of using nicotinamide riboside to promote the increase of intracellular levels of nicotinamide adenine dinucleotide (NAD+) in cells and tissues for improving cell and tissue survival. A method of treating signs or symptoms of aging or skin wrinkles in an individual is provided, comprising topically administering to the individual in need of such treatment an effective amount of the compound nicotinamide riboside, or salts thereof.
    Type: Application
    Filed: October 30, 2014
    Publication date: September 1, 2016
    Applicant: CHROMADEX INC.
    Inventors: Ann Deren-Lewis, Troy Rhonemus
  • Publication number: 20150011650
    Abstract: A method is provided for treating an individual for a cellular proliferative disorder, including administering to the individual in need of such treatment a therapeutically effective amount of the compound pterostilbene wherein UDP-glucuronosyltransferase (UGT) activity is increased. In an embodiment, 12-HETE levels can be reduced by administration of pterostilbene.
    Type: Application
    Filed: September 22, 2014
    Publication date: January 8, 2015
    Applicants: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, CHROMADEX INC.
    Inventors: Jeremy Bartos, Ryan Dellinger
  • Patent number: 8841350
    Abstract: A method is provided for treating an individual for a cellular proliferative disorder, including administering to the individual in need of such treatment a therapeutically effective amount of the compound pterostilbene wherein UDP-glucuronosyltransferase (UGT) activity is increased. In an embodiment, 12-HETE levels can be reduced by administration of pterostilbene.
    Type: Grant
    Filed: May 8, 2012
    Date of Patent: September 23, 2014
    Assignees: ChromaDex Inc., The Regents of the University of California
    Inventors: Jeremy Bartos, Ryan Dellinger
  • Publication number: 20130296440
    Abstract: A pharmaceutical composition is provided comprising a therapeutically effective amount of pterostilbene, a therapeutically effective amount of curcumin, and a pharmaceutically acceptable carrier. The embodiments of the pharmaceutical compositions can have lipid lowering properties, or alternatively can have properties that can treat oxidative stress, by decreasing inflammation or inflammatory processes contributing to digestive disorders or cancer. A method of treating an individual for an inflammatory disorder is provided, comprising administering to the individual in need of such treatment a pharmaceutical composition including a therapeutically effective amount of pterostilbene, a therapeutically effective amount of a curcumin, and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: April 30, 2013
    Publication date: November 7, 2013
    Applicant: ChromaDex Inc.
    Inventor: Jeremy Bartos
  • Publication number: 20130149277
    Abstract: A pharmaceutical composition is provided comprising a therapeutically effective amount of pterostilbene, a therapeutically effective amount of a polyphenolic-PVP extract of grape juice, and a pharmaceutically acceptable carrier. The embodiments of the pharmaceutical compositions can have lipid lowering properties, or alternatively can have properties that can treat oxidative stress, by decreasing inflammation or inflammatory processes contributing to neurodegenerative diseases. A method of lowering lipid levels in an individual is also provided, comprising administering to the individual in need of such treatment a pharmaceutical composition including a therapeutically effective amount of pterostilbene, a therapeutically effective amount of a polyphenolic-PVP extract of grape juice, and a pharmaceutically acceptable carrier, wherein lipid levels are decreased.
    Type: Application
    Filed: December 12, 2012
    Publication date: June 13, 2013
    Applicants: Cliffstar LLC, ChromaDex Inc.
    Inventors: ChromaDex Inc., Cliffstar LLC
  • Publication number: 20130072509
    Abstract: A pharmaceutical composition is provided comprising a therapeutically effective amount of pterostilbene, a therapeutically effective amount of a statin compound, and a pharmaceutically acceptable carrier. The embodiments of the pharmaceutical compositions can have lipid lowering properties, or alternatively can have properties that can treat oxidative stress, by decreasing inflammation or inflammatory processes contributing to neurodegenerative diseases. A method of lowering lipid levels in an individual is also provided, comprising administering to the individual in need of such treatment a pharmaceutical composition including a therapeutically effective amount of pterostilbene, a therapeutically effective amount of a statin compound, and a pharmaceutically acceptable carrier, wherein lipid levels are decreased.
    Type: Application
    Filed: September 14, 2012
    Publication date: March 21, 2013
    Applicant: ChromaDex Inc.
    Inventor: Jeremy Bartos
  • Publication number: 20120289605
    Abstract: A method is provided for treating an individual for a cellular proliferative disorder, including administering to the individual in need of such treatment a therapeutically effective amount of the compound pterostilbene wherein UDP-glucuronosyltransferase (UGT) activity is increased. In an embodiment, 12-HETE levels can be reduced by administration of pterostilbene.
    Type: Application
    Filed: May 8, 2012
    Publication date: November 15, 2012
    Applicants: The Regents of the University of California, ChromaDex Inc.
    Inventors: Jeremy Bartos, Ryan Dellinger